Welcome to our dedicated page for Asensus Surgical news (Ticker: ASXC), a resource for investors and traders seeking the latest updates and insights on Asensus Surgical stock.
Asensus Surgical, Inc. (NYSE American: ASXC) is a trailblazing medical device company that enhances minimally invasive surgery through digital laparoscopy. The company's flagship product, the Senhance® Surgical System, is the first machine vision system used in robotic surgery. It leverages augmented intelligence, connectivity, and robotics to address clinical, cognitive, and economic challenges in surgery.
Headquartered in Research Triangle Park, North Carolina, Asensus Surgical focuses exclusively on the research, development, and sale of medical device robotics aimed at improving surgical outcomes. The company's cutting-edge technology includes the Intelligent Surgical Unit™ that brings augmented intelligence into the operating room. One of its latest innovations is the LUNA™ Surgical System, a next-generation robotic and instrument system under development.
Committed to global healthcare improvements, Asensus Surgical has expanded its reach with the Senhance System now available in the US, EU, Japan, Russia, and select other countries. The system has recently been adopted by Nagoya University Hospital in Japan, dedicated to pediatric procedures. This marks a significant milestone, as the Senhance System offers specialized instrumentation and advanced clinical intelligence, aimed at reducing invasiveness and increasing precision in pediatric surgery.
In a recent strategic move, Asensus Surgical entered into a definitive merger agreement with KARL STORZ Endoscopy-America, Inc., a subsidiary of KARL STORZ SE & Co. KG. This merger, valued at $0.35 per share, is anticipated to enhance KARL STORZ's portfolio and market presence, particularly in the robotic surgical market. The transaction has been unanimously approved by Asensus’ Board of Directors and is expected to close during the third quarter of 2024.
Asensus Surgical continues to be driven by collaboration and human ingenuity, striving to make surgery more accessible and predictable while delivering consistently superior outcomes. For more detailed information, visit www.asensus.com.
Asensus Surgical, Inc. (NYSE American: ASXC) has announced that CEO Anthony Fernando and CFO Shameze Rampertab will participate in the Oppenheimer 33rd Annual Healthcare Conference. Their virtual presentation is scheduled for March 13, 2023, at 2:00 pm Eastern Time.
The presentation will be available for live streaming on the company's investor relations page, with replays archived for 90 days. Asensus is focused on digitizing surgical interfaces through innovative technologies like the Senhance® Surgical System and the upcoming LUNA™ Surgical System, enhancing surgical precision and outcomes.
Asensus Surgical (ASXC) announced its operating and financial results for Q4 and FY 2022, reporting revenue of $2.5 million in Q4, unchanged from the previous year, while full-year revenue totaled $7.1 million, reflecting growth from 2021. The company performed over 840 surgical procedures in Q4, a 29% increase from Q4 2021, and over 3,100 for the full year. Asensus highlighted significant partnerships, including a collaboration with Google Cloud and plans for the LUNA Surgical System. However, the company incurred a net loss of $17.9 million in Q4 2022 and $60.4 million for the full year, raising concerns about its financial sustainability.
Asensus Surgical, Inc. (ASXC) announced plans to release its fourth-quarter and full-year 2022 financial results on March 2, 2023, after market close. The company recently held an Investor Day on February 21, 2023, which provided an in-depth review of its business operations. Asensus will not hold a separate earnings conference call following the release, but a video replay of the Investor Day is available on their investor relations page. The company focuses on digitizing surgery through its technology, including the Senhance Surgical System and the upcoming LUNA Surgical System, aimed at enhancing surgical outcomes and value-based healthcare.
Asensus Surgical, Inc. (NYSE American: ASXC) presented a corporate update during its February 21, 2023, Investor Day. The company aims to transform surgery through its Performance-Guided Surgery framework, leveraging advancements in digital laparoscopy via its Senhance® Surgical System and Intelligent Surgical Unit™ (ISU). A highlight is the upcoming LUNA™ Surgical System, designed from insights garnered over 10,000 procedures. Key features of the ISU include real-time analytics and machine-learning capabilities. Collaborative efforts with Google Cloud and KARL STORZ aim to enhance clinical insights and market reach. The LUNA Surgical System remains in development, with no current market availability.
Asensus Surgical (NYSE American: ASXC) has announced a Memorandum of Understanding with KARL STORZ VentureONE, focusing on the development of advanced surgical technology. This partnership aims to enhance the Intelligent Surgical Unit (ISU) by integrating it with KARL STORZ's imaging systems and jointly creating next-generation surgical instruments. The two companies plan to finalize definitive agreements in the next 90 days. Asensus aims to leverage KARL STORZ's extensive market presence to expand the reach of the ISU, enhancing surgical outcomes through augmented intelligence and improved instrument design.
Asensus Surgical announced a multi-year collaboration with Google Cloud to enhance its Performance-Guided Surgery™ (PGS) framework through secure cloud data architecture and machine learning. This partnership aims to improve surgical accuracy and patient outcomes by integrating advanced data analytics and augmented intelligence into surgical procedures. Asensus plans to provide analytics tools to surgeons and hospitals, leveraging Google Cloud's capabilities. Further details will be shared during Asensus’ investor day on February 21, 2023. Together, the collaboration seeks to revolutionize surgical practices and enhance the digital surgical interface.
On February 21, 2023, Asensus Surgical (ASXC) will celebrate a significant milestone by ringing the opening bell at the New York Stock Exchange, marking its ongoing commitment to innovation. CEO Anthony Fernando expressed pride in representing the company, emphasizing its focus on enhancing surgical outcomes. The event coincides with an Investor Day at 11:30 AM EST, featuring a live webcast for attendees. Asensus Surgical is dedicated to digitizing the surgical interface, aiming to improve results through the Senhance Surgical System and advanced technologies like machine vision and deep learning, now available in multiple countries including the US and EU.
Asensus Surgical, Inc. (NYSE American: ASXC) announced an Investor Day scheduled for February 21, 2023, at the InterContinental New York Barclay Hotel. The event begins at 11:30 AM EST and will feature a live webcast available on the company’s investor relations page.
Asensus is focused on Performance-Guided Surgery, leveraging its Senhance® Surgical System to enhance surgical outcomes through advanced technologies like machine vision and deep learning. The system aims to address the current challenges in surgical practices, reinforcing the company's commitment to redefining surgical standards.
Asensus Surgical, Inc. (ASXC) has received CE Mark approval for the expansion of its Intelligent Surgical Unit™ (ISU™) capabilities, now available in Europe, Japan, and the U.S. This enhancement includes 3D measurement, digital tagging, image enhancement, and improved camera control, aligning with the EU's stricter Medical Device Regulation (MDR). The Senhance® Surgical System is one of the first robotic surgical systems cleared under this new process. CEO Anthony Fernando emphasized the surgery community's positive feedback on these innovations as they aim to enhance real-time surgical tools, reflecting the company’s commitment to Performance-Guided Surgery™.
Asensus Surgical (ASXC) reported strong growth in its preliminary year-end results for 2022, highlighting over 26% increase in global procedures with around 2,650 performed. The fourth quarter alone saw more than 690 procedures, a 23% rise from the previous year. The estimated revenue for Q4 is $2.2-$2.8 million, while the full year revenue ranges from $6.8-$7.4 million. The company initiated nine new Senhance Surgical Programs in 2022, focusing on Germany, Japan, and the CIS region. With approximately $74.4 million in cash and investments as of year-end, Asensus is poised for future growth.
FAQ
What is the current stock price of Asensus Surgical (ASXC)?
What is the market cap of Asensus Surgical (ASXC)?
What does Asensus Surgical, Inc. do?
Where is Asensus Surgical headquartered?
What is the Senhance® Surgical System?
What is the latest innovation from Asensus Surgical?
In which regions is the Senhance® Surgical System available?
Has Asensus Surgical recently partnered with any hospitals?
What is the merger agreement with KARL STORZ about?
When is the merger with KARL STORZ expected to close?
Will Asensus Surgical continue to be publicly traded after the merger?
How can I learn more about Asensus Surgical's products?
